Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2019 | Resistance to IMiDs in MM

Enrique Ocio • 15 Jun 2019
EHA 2019
Multiple Myeloma

Enrique Ocio, MD, PhD, Marquis of University Hospital Marqués de Valdecilla, Santander, Spain, discusses his work into assessing the mechanisms of resistance to IMiDs in multiple myeloma. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Enrique Ocio

Isa-VRd in older patients with/without frailty criteria: pooled analysis in newly diagnosed myeloma 3:08
Isa-VRd in older patients with/without frailty criteria: pooled analysis in newly diagnosed myeloma
Enrique Ocio • 6 Dec 2025
The possibility of integrating CELMoDs, CAR T-cells & bispecifics into first-line therapy in myeloma 1:28
The possibility of integrating CELMoDs, CAR T-cells & bispecifics into first-line therapy in myeloma
Enrique Ocio • 8 Dec 2024
Unmet needs in multiple myeloma: patients who are refractory to T-cell engagers and CAR-Ts 1:08
Unmet needs in multiple myeloma: patients who are refractory to T-cell engagers and CAR-Ts
Enrique Ocio • 8 Dec 2024
A pilot study investigating a shorter duration of isatuximab infusion in patients with myeloma 1:16
A pilot study investigating a shorter duration of isatuximab infusion in patients with myeloma
Enrique Ocio • 8 Dec 2024

Related Videos

Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
Prolonged elranatamab treatment interruption in R/R myeloma: MagnetisMM-3 retrospective analysis 2:35
Prolonged elranatamab treatment interruption in R/R myeloma: MagnetisMM-3 retrospective analysis
Alexander Lesokhin • 8 Dec 2025
Integrated approaches to improve prognosis prediction in multiple myeloma 2:32
Integrated approaches to improve prognosis prediction in multiple myeloma
Claudio Cerchione • 6 Dec 2025
The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma 4:45
The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma
Ola Landgren • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals